Posted by Michael Wonder on 17 Oct 2019
ICER issues final report and policy recommendations regarding additive treatments for cardiovascular disease
17 October 2019 - Independent appraisal committee votes that rivaroxaban and icosapent ethyl improve patient health at prices that achieve good long-term value for money, but the large potential short-term budget impact associated with treating even a small percentage of eligible US patients leads ICER to issue an Access and Affordability Alert.
The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and long-term value for money of rivaroxaban (Xarelto, Janssen Pharmaceuticals), and icosapent ethyl (Vascepa, Amarin Pharma).
ICER’s report on these additive treatments for cardiovascular disease was reviewed at the September 2019 public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER’s three independent evidence appraisal committees.
